Investment Advisor Trims Small-Cap Tech Stock Position by $2.5 Million, According to Recent SEC Filing

Meros Investment Management disclosed that it sold 70,437 shares of Photronics in Q1 2026, an estimated $2.55 million trade that reduced the PLAB position to 37,567 shares worth $1.52 million. The position’s quarter-end value fell $1.94 million, and PLAB now represents 0.66% of AUM, outside the fund’s top five holdings. The filing is routine portfolio activity rather than a company-specific operating update.

Analysis

PLAB is increasingly a crowded “good story” rather than a clean value/quality setup. A stock that has already re-rated sharply tends to become more sensitive to position trimming by fundamentals-aware managers, because the marginal buyer shifts from long-term compounders to momentum and event-driven holders; that makes the next leg more dependent on incremental earnings revisions than on narrative alone.

The more important second-order readthrough is not the sell itself, but the signal that the opportunity set may be better in the manager’s other semiconductor-adjacent holdings than in a photomask name with a stretched multiple. If AI-related capex stays firm, PLAB can still participate, but the upside asymmetry is likely lower than peers with cleaner operating leverage or less rerating baggage. In other words, this looks like an allocation rotation away from an overcrowded beneficiary, not a call that the end-market is broken.

Risk is mostly timing: over the next 1-3 months, PLAB can keep drifting higher if front-end semiconductor demand and display-related utilization stay tight. The real downside catalyst is any pause in foundry capex or a normalization in the AI spend trade, because the stock’s current multiple leaves little margin for a growth hiccup. Consensus appears to be underestimating how quickly multiple compression can offset still-healthy fundamentals once the growth rate starts to decelerate.

Key Decisions for Investors

• Trim or avoid chasing PLAB at current levels; use strength to reduce exposure unless you have a 6-12 month view that revenue growth will re-accelerate enough to justify further multiple expansion.
• Favor a pair trade: long NVDA, short PLAB for 3-6 months. NVDA has the cleaner AI capex capture and stronger earnings revision momentum; PLAB carries higher valuation risk if the market rotates away from the ‘everything AI’ basket.
• If holding semicap exposure, rotate from PLAB into higher-beta operating leverage names only on pullbacks; PLAB is now more of a momentum asset than a mispriced fundamental compounder.
• For tactical traders, buy downside protection on PLAB via 2-3 month puts or put spreads. The setup is vulnerable to a 10-15% de-rating if guidance or sector sentiment wobbles.